Semper Paratus Acquisition Corporation (NASDAQ:TVGN) Short Interest Update

Key Points

• Short Interest Surge: Semper Paratus Acquisition Corporation (NASDAQ:TVGN) experienced a dramatic increase in short interest, up by 3,719.3% to 1,860,000 shares as of July 15th, representing 4.6% of its total shares.
• Insider Sale: CEO Ryan H. Saadi sold over 1.4 million shares of stock on June 9th for approximately $1.77 million, reducing their ownership position by 1.22% while still holding 116.8 million shares.
• Institutional Investment Activity: Geode Capital Management and Barclays PLC were among institutional investors that increased their stakes in Semper Paratus Acquisition in the fourth quarter, highlighting ongoing institutional interest.

Semper Paratus Acquisition Corporation (NASDAQ:TVGN - Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,860,000 shares, anincreaseof3,719.3% from the June 30th total of 48,700 shares. Currently,4.6% of the shares of the company are sold short. Based on an average daily volume of 975,400 shares, the short-interest ratio is presently 1.9 days. Based on an average daily volume of 975,400 shares, the short-interest ratio is presently 1.9 days. Currently,4.6% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a "buy" rating and set a $10.00 price target on shares of Semper Paratus Acquisition in a research report on Monday.

Semper Paratus Acquisition Trading Up 1.2%

Shares of Semper Paratus Acquisition stock traded up $0.01 during trading on Tuesday, hitting $1.01. 147,681 shares of the company were exchanged, compared to its average volume of 1,360,796. Semper Paratus Acquisition has a fifty-two week low of $0.26 and a fifty-two week high of $3.09. The firm has a 50 day moving average price of $1.20 and a 200 day moving average price of $1.21.

Insider Buying and Selling

In related news, CEO Ryan H. Saadi sold 1,438,206 shares of the firm's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $1.23, for a total value of $1,768,993.38. Following the completion of the sale, the chief executive officer owned 116,814,453 shares in the company, valued at $143,681,777.19. This trade represents a 1.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 73.24% of the stock is currently owned by insiders.

Institutional Trading of Semper Paratus Acquisition

Several hedge funds and other institutional investors have recently bought and sold shares of TVGN. Barclays PLC lifted its holdings in shares of Semper Paratus Acquisition by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after acquiring an additional 12,847 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Semper Paratus Acquisition by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock valued at $122,000 after acquiring an additional 13,595 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Semper Paratus Acquisition by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock worth $40,000 after buying an additional 16,695 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Semper Paratus Acquisition by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock worth $465,000 after buying an additional 107,566 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Semper Paratus Acquisition in the 4th quarter worth $55,000.

Semper Paratus Acquisition Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.